These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15320716)

  • 1. p53: fighting cancer.
    Selivanova G
    Curr Cancer Drug Targets; 2004 Aug; 4(5):385-402. PubMed ID: 15320716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppression by p53: the importance of apoptosis and cellular senescence.
    Zuckerman V; Wolyniec K; Sionov RV; Haupt S; Haupt Y
    J Pathol; 2009 Sep; 219(1):3-15. PubMed ID: 19562738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage.
    Yoshida K; Miki Y
    Cancer Sci; 2010 Apr; 101(4):831-5. PubMed ID: 20132225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53: a guide to apoptosis.
    Meulmeester E; Jochemsen AG
    Curr Cancer Drug Targets; 2008 Mar; 8(2):87-97. PubMed ID: 18336191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 rescue and modulation of p53 redox state.
    Bykov VJ; Lambert JM; Hainaut P; Wiman KG
    Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
    Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
    Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.
    Fei P; Wang W; Kim SH; Wang S; Burns TF; Sax JK; Buzzai M; Dicker DT; McKenna WG; Bernhard EJ; El-Deiry WS
    Cancer Cell; 2004 Dec; 6(6):597-609. PubMed ID: 15607964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of apoptotic response in cellular resistance to cytotoxic agents.
    Zunino F; Perego P; Pilotti S; Pratesi G; Supino R; Arcamone F
    Pharmacol Ther; 1997; 76(1-3):177-85. PubMed ID: 9535179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer].
    Sznarkowska A; Olszewski R; Zawacka-Pankau J
    Postepy Hig Med Dosw (Online); 2010 Aug; 64():396-407. PubMed ID: 20966497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-suppressor p53: implications for tumor development and prognosis.
    Kirsch DG; Kastan MB
    J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of p53 activation--spoilt for choice.
    Vousden KH
    J Cell Sci; 2006 Dec; 119(Pt 24):5015-20. PubMed ID: 17158908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p53 by specific agents in potential cancer therapy.
    Ho JW; Song JZ; Leung YK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):131-5. PubMed ID: 15777220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
    Bykov VJ; Wiman KG
    Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
    Puca R; Nardinocchi L; Givol D; D'Orazi G
    Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level.
    Amellem O; Stokke T; Sandvik JA; Smedshammer L; Pettersen EO
    Exp Cell Res; 1997 May; 232(2):361-70. PubMed ID: 9168813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
    Chari NS; Pinaire NL; Thorpe L; Medeiros LJ; Routbort MJ; McDonnell TJ
    Apoptosis; 2009 Apr; 14(4):336-47. PubMed ID: 19229632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the p53-family in cancer and chemosensitivity: triple threat.
    Chung J; Irwin MS
    Curr Drug Targets; 2010 Jun; 11(6):667-81. PubMed ID: 20298155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of the p53 pathway, apoptosis and cancer therapy.
    Vazquez A; Bond EE; Levine AJ; Bond GL
    Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.